Peter S. Linsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peter S. Linsley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aimee L. Jackson
Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
3 shared publications Alan B. Sachs
Sirna Therapeutics, San Francisco, California 94185, USA
1 shared publicationHongyue Dai
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
1 shared publicationJulja Burchard
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
1 shared publicationRachel H.V. Needham
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
1 shared publicationSteven R. Bartz
Sirna Therapeutics, San Francisco, California 94185, USA
1 shared publication
Latest Publications
- Open Access
- 11 May 2010
- Published by Springer Nature in BMC Biology
- Vol. 8 (1) , 53
Hidden reach of the micromanagers
Small interfering RNAs can trigger unintended, microRNA-like off-target effects, but the impact of these effects on functional studies has been controversial. A recent study in BMC Genomics shows that microRNA-like effects can predominate among the 'hits' of functional genomics screens.
- 11 May 2010
- Published by Springer Nature in BMC Biology
- Vol. 8 (1) , 53
Open AccessHidden reach of the micromanagers
Small interfering RNAs can trigger unintended, microRNA-like off-target effects, but the impact of these effects on functional studies has been controversial. A recent study in BMC Genomics shows that microRNA-like effects can predominate among the 'hits' of functional genomics screens.
- 1 April 2010
- Vol. 9 (47) , 311-8
The therapeutic potential of microRNA modulation.
MicroRNAs are endogenous small non-coding RNAs that regulate gene expression by interfering with translation or stability of target transcripts. The importance and varied functions of microRNAs are illustrated by the diverse phenotypes, including disease, that arise when microRNAs are mutated or improperly expressed. The association of microRNA dysfunction with disease phenotypes has given rise to the idea that selective modulation of microRNAs could alter the course of disease. With the recent demonstration that inhibition of miR-122 reduces viral load in HCV-infected chimpanzees, microRNA modulators are no longer merely theoretical, but have become strong candidate therapeutics. Here we review the evidence for microRNA dysfunction in human disease, as well as recent examples of microRNA modulation that provided therapeutic benefit.
- 1 April 2010
- Vol. 9 (47) , 311-8
The therapeutic potential of microRNA modulation.
MicroRNAs are endogenous small non-coding RNAs that regulate gene expression by interfering with translation or stability of target transcripts. The importance and varied functions of microRNAs are illustrated by the diverse phenotypes, including disease, that arise when microRNAs are mutated or improperly expressed. The association of microRNA dysfunction with disease phenotypes has given rise to the idea that selective modulation of microRNAs could alter the course of disease. With the recent demonstration that inhibition of miR-122 reduces viral load in HCV-infected chimpanzees, microRNA modulators are no longer merely theoretical, but have become strong candidate therapeutics. Here we review the evidence for microRNA dysfunction in human disease, as well as recent examples of microRNA modulation that provided therapeutic benefit.
- 14 January 2009
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 15 (2) , 308-315
MicroRNA-like off-target transcript regulation by siRNAs is species specific
SiRNAs mediate sequence-specific gene silencing in cultured mammalian cells but also silence unintended transcripts. Many siRNA off-target transcripts match the guide-strand “seed region,” similar to the way microRNAs match their target sites. The extent to which this seed-matched, microRNA-like, off-target silencing affects the specificity of therapeutic siRNAs in vivo is currently unknown. Here, we compare microRNA-like off-target regulations in mouse liver in vivo with those seen in cell culture for a series of therapeutic candidate siRNAs targeting Apolipoprotein B (APOB). Each siRNA triggered regulation of consistent microRNA-like off-target transcripts in mouse livers and in cultured mouse liver tumor cells. In contrast, there was only random overlap between microRNA-like off-target transcripts from cultured human and mouse liver tumor cells. Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models.
- 14 January 2009
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 15 (2) , 308-315
MicroRNA-like off-target transcript regulation by siRNAs is species specific
SiRNAs mediate sequence-specific gene silencing in cultured mammalian cells but also silence unintended transcripts. Many siRNA off-target transcripts match the guide-strand “seed region,” similar to the way microRNAs match their target sites. The extent to which this seed-matched, microRNA-like, off-target silencing affects the specificity of therapeutic siRNAs in vivo is currently unknown. Here, we compare microRNA-like off-target regulations in mouse liver in vivo with those seen in cell culture for a series of therapeutic candidate siRNAs targeting Apolipoprotein B (APOB). Each siRNA triggered regulation of consistent microRNA-like off-target transcripts in mouse livers and in cultured mouse liver tumor cells. In contrast, there was only random overlap between microRNA-like off-target transcripts from cultured human and mouse liver tumor cells. Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models.